Associated Papers
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Heymach JV et al.
Expert Review of Anticancer Therapy, 2026
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer.
Fu Z et al.
Cancer Cell, 2026
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer-Predisposing Factors in Familial Early-Onset Colorectal Cancer.
Bagheri B et al.
The Kaohsiung Journal of Medical Sciences, 2026
Comprehensive Molecular Docking and Molecular Dynamics Reveal Inhibitors of HER2 L755S, T798I, and T798M based on a Large Database of Curcumin Derivatives.
Gusrin MSD et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2026
Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression.
Kader T et al.
The Journal of Pathology, 2026
The GigaAssay: A combined high throughput and highly accurate platform for variant classification.
Giacoletto CJ et al.
New Biotechnology, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma.
Huang X et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Enhanced computational strategies for categorizing HER2 kinase domain variants of uncertain significance through structural and functional analysis.
Loganathan T et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2025
Translating genomic insights into therapy: an NGS-based mutation profiling study in breast cancer.
Bhavnagari HM et al.
Medical Oncology (northwood, London, England), 2025
High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.
Giacoletto CJ et al.
Genomics, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients.
Sandbothe M et al.
Virchows Archiv : an International Journal of Pathology, 2025
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
Shimauchi A et al.
British Journal of Cancer, 2025
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.
Vandekerkhove G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
HER2 alterations across solid tumors: implications for comprehensive testing.
Ismail A et al.
The Oncologist, 2025
Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pons L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.
Egebjerg K et al.
Bmc Cancer, 2025
Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations.
Hoda RS et al.
Human Pathology, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
[Characteristics of KRAS and HER-family gene mutations in ampullary cancer].
Zeng LL et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.
Nogueira CD et al.
Oncotarget, 2025
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer.
Pathak V et al.
Hgg Advances, 2025
Comprehensive germline and somatic profiling of high-risk Thai breast cancer via next-generation sequencing.
Kamdee K et al.
Scientific Reports, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts.
Pilati C et al.
Gastroenterology, 2025
Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry.
Korentzelos D et al.
Human Pathology, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
De A et al.
Research Square, 2025
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies.
Veas Rodriguez J et al.
Journal for Immunotherapy of Cancer, 2025
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.
Giacoletto CJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.
Xiang Y et al.
Current Oncology (toronto, Ont.), 2025
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Manrai PA et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 2025
Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR).
Yi SA et al.
Molecular Oncology, 2025
MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors.
Kaczorowski M et al.
The Journal of Pathology. Clinical Research, 2025
PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models.
Chen H et al.
Molecular Cancer Therapeutics, 2025
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W et al.
International Journal of Molecular Medicine, 2025